Electron-capture GLC determination of a new antiarrhythmic agent, alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl) benzylamine, in biological fluids.
A highly specific and sensitive GLC method was developed for the analysis of alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl) benzylamine, a new orally active antiarrhythmic drug, in biological fluids. The procedure involves the addition of an internal standard, 4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine, to the plasma or urine samples followed by extraction of the drugs into benzene at pH 8. The extracted amines are converted to the trifluoroacetyl derivatives (characterized by GLG-mass spectrometry), chromatographed, and detected with a 63Ni electron-capture detector. The sensitivity of the method is such that 10 ng of alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine/ml of plasma can be analyzed. These levels are suitable for the analysis of samples obtained following a therapeutic dose.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000032:analysis* / Q000378:metabolism; D001593:Benzyl Compounds / Q000032:analysis* / Q000378:metabolism; D002849:Chromatography, Gas; D004285:Dogs; D006207:Half-Life; D007408:Intestinal Absorption; D013058:Mass Spectrometry; D009532:Nickel; D011868:Radioisotopes
D000889:Anti-Arrhythmia Agents; D001593:Benzyl Compounds; D011868:Radioisotopes; D009532:Nickel